336 results about "Intestinal juice" patented technology

A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice; and (c) a second coating applied to the surface of the first coating.

The invention relates to a pharmaceutical formulation containing essentially a) an inner layer which can optionally be applied to a core, with the active substance budesonide, bound with a binding agent; b) a middle layer with a polymer covering agent which is soluble in intestinal juice or retardant; and c) an outer envelope or outer layer which is resistant to stomach juice, said layers being able to contain in a manner known per se other pharmaceutically usual adjutants. The inventive formulation is characterised in that the binding agent is a polymer or a copolymer with acid groups and the formulation of the inner layer without the middle and outer layer releases the bound active ingredient in a release test according to USP XXIII monography <711> dissolution with apparatus 2 (addle) at a rotational speed of 100/min in a phosphate buffer pH 7.5 after 30 min to a value of more than 80%.

The invention discloses a quality control method of metformin hydrochloride enteric coated tablet, comprising the aspects of character, identification, examination and content measurement; wherein, release examination comprises the release quantity examination of acid in hydrochloric acid solution of 0.1 mol/l and the release quantity examination in phosphate buffer with the pH value of 6.8; the examination of relevant substances comprises the following steps: dicyandiamide is taken as reference, sulfonic group cation exchange bonded silica is taken as filler, ammonium dihydrogen phosphate solution of 1.7 percent with the pH value of 3 is mobile phase and the high performance liquid chromatography is used for examining the relevant substances. The invention controls the release quantity of the metformin hydrochloride enteric coated tablet in gastric juice strictly, reduces the adverse reaction of patients effectively, improves the release quantity of the metformin hydrochloride enteric coated tablet in the buffer solution (simulated intestinal juice) and ensures the dissolution of the enteric coated tablet in the intestinal juice effectively; the invention also adds the examination of dicyandiamide impurity under the examination item and enhances the safety of the medicine.

The invention relates to an enteric plant hollow capsule which is prepared by a method comprising: firstly adding 60-85% of pectin, 5-20% of plasticizer, 5-10% of coagulant aid and 5-10% of water used for curing agent into a reaction pot; stirring and dissolving at 60-90 DEG C, and obtaining glue stock by filtering and adjusting specific gravity; removing air bubbles and then sending into a capsule production line for the treatment such as dipping in glue, drying, cooling, demoulding, cutting, sheathing, etc. The enteric plant hollow capsule has the disintegration time limit of 3-4h in gastric juice and 30-45min in intestinal juice. Compared with the existing enteric capsule, the enteric plant hollow capsule omits the working procedure of coating, simplifies the technique, and completely uses no organic solvent, thus not only being beneficial to safe production and environmental protection, but also being beneficial to improving the efficiency and reducing the cost.

The invention discloses a Pickering emulsion as well as a preparation method thereof. The Pickering emulsion comprises the following components in percentage by weight: 0.05-3% of starch nanocrystals, 0.001-2% of amino acids, 10-90% of edible oil and the balance of water. The prepared Pickering emulsion remains stable in a wide acidic range with the pH of 1-5; under an alkaline condition, the demulsification time of the emulsion can be controlled by adjusting the type of starch nanocrystals and amino acids which are compounded and used as well as the concentration and proportion of starch nanocrystals and amino acids; meanwhile, in a process of simulating human digestion, the Pickering emulsion disclosed by the invention achieves the slow-release effect of being stable in gastric juice and being released in intestinal juice. Therefore, the Pickering emulsion disclosed by the invention can be used as a safe and effective controlled release system for stomach and intestine for conveying active components in foods, health products or drugs, and has a relatively good application prospect.

The invention provides bacillus subtilis (Bacillussubtilis) shou003, an anti-vibrio protein and a preparation method and applications of the bacillus subtilis shou003 and the anti-vibrio protein. The preparation method of the anti-vibrio protein comprises the following steps: screening out bacillus subtilis shou003 (preserved in China Center for Type Culture Collection with a number of CCTCC No.: M2013571 on November 13, 2013) from intestinal tract of a healthy large yellow croaker; and then extracting the anti-vibrio protein from the fermentation broth of bacillus subtilis shou003, wherein the amino acid sequence of the anti-vibrio protein is shown as SEQ ID No.: 1. The bacillus subtilis shou003 and the anti-vibrio protein show good effects on inhibiting aquatic pathogenic bacteria, in particular pathogenic vibrio; in addition, the bacillus subtilis shou003 shows outstanding tolerance to temperature, NaCl, gastric juice, intestinal juice and cholate and can be widely applied to the prevention of germs during aquaculture; on that basis, the optimal fermentation culture method of the bacillus subtilis shou003, and a preparation method of the anti-vibrio protein are provided.

The invention belongs to the technical field of chemical synthetic medicines and particularly relates to water soluble salts of an organic acid of 5-(2-fluorophenyl)-N-methyl-1-(3-pyridyl sulfonyl)-1H-pyrrole-3-methylamine and an injection thereof for treating gastric acid related diseases and a preparation method thereof. The invention discloses the salts of the organic acid of 5-(2-fluorophenyl)-N-methyl-1-(3-pyridyl sulfonyl)-1H-pyrrole-3-methylamine shown as the following general formula in the specification, wherein n is 1 or 1/2 and HA is an organic acid. According to the salts of the organic acid, which are disclosed by the invention, the solubility of the salts in water or an artificial gastric and intestinal juice is far greater than TAK438, and the solubility of pyroglutamate and lactate in water is greater than 1g/mL.

Provided are a power generation system which does not limit a patient's range of motion, is harmless to a living body, and can obtain a sufficient electricity generating capacity in the stomach or the intestines and a disposable medical capsule device which does not have to be collected after use. A power supply system is mounted in the capsule device, comprises an electrode pair including at least two electrodes provide on an outer wall surface of a capsule main body, for example, an aluminum electrode and a catalyst-supporting carbon electrode, generates power when immersed in an electrolytic solution consisting of gastric juice or intestinal juice, and supplies the power to constituent portions in the capsule device.

The invention provides an engineering strain of recombinant expression lipase. Lipase gene obtained by cloning in Aspergillus niger is transferred into Trichoderma reesei, so that Trichoderma reesei engineering strain can be constructed and has the preservation number of China Center for Type Culture Collection (CCTCC) No.: M2012483. The recombinant expression lipase has the optimal action pH of 5.0 and the optimal action temperature of 30 DEG C, and the tolerance of the recombinant expression lipase to gastric juice, pepsase and artificial intestinal juice can be enhanced. The lipase remarkably improves the utilization rate of oil matter in feed, thus remarkably reducing the addition of oil in the feed and reducing the cost of the feed.

The invention discloses a sinomenine or an enteric-coated controlled-release tablet of hydrochloride thereof. The prepared enteric-coated controlled-release tablet hardly releases the drug in artificial simulated gastric juice, but can slowly and smoothly release the drug in artificial simulated intestinal juice; the sustained release time of the drug can achieve more than 12 hours or even 24 hours; the enteric-coated controlled-release tablet is taken once or twice daily, the plasma drug concentration in vivo is smooth, and the peak-valley phenomenon of the plasma drug concentration is reduced; as the prepared enteric-coated controlled-release tablet hardly releases the drug in stomach, the contacted concentration of the drug with the gastric mucosa is small, the stimulation of the stomach caused by the drug is alleviated. As the prepared enteric-coated controlled-release tablet sustainedly slowly releases the drug in intestinal tract, the times of the drug administration are reduced, and the patient compliance is improved, thereby being applicable to the needs of the clinical development.

The invention relates to the technical field of microorganisms, and particularly provides Lactobacillus reuteri and application thereof. The Lactobacillus reuteri provided by the invention is a canine-derived Lactobacillus reuteri strain which is separated from hindgut content of a healthy adult blue fox for the first time by an inventor, and the preservation number of the Lactobacillus reuteri isCCTCC NO: M 2018943. The strain has good growth performance, is high in tolerance to gastric juice and intestinal juice and good in adhesion to small intestine epithelial cells, can promote proliferation of dog intestinal tract beneficial bacteria, can inhibit growth of harmful bacteria, can enhance the immune function of pet dog organisms, has better effect than that of similar products in the market, can serve as an alternative strain of probiotic preparations, and is quite wide in application prospect.

The invention belongs to the technical field of biomedicines and discloses albumin nanoparticles covering pharmacological active substances as well as a preparation method and application thereof. Thepreparation method comprises the following steps: opening an inner space structure of albumin under the action of glutathione to form protein containing a sulfydryl group active radical; adding a selenium compound and the pharmacological active substances; obtaining the albumin nanoparticles covering the pharmacological active substances by utilizing intramolecular or intermolecular sulfydryl-selenium-sulfur bond exchange reaction and sulfydryl-disulfide bond exchange reaction and elemental selenium which is loaded at inner and outer parts of a protein cavity. The method has the advantages ofsimplicity in operation; a novel albumin binding type nano-preparation has the advantages of uniform size, good dispersity and long preservation time at room temperature, and good stability in gastric acid, intestinal juice and blood serum; the solubility, dispersity, stability and bioavailability of lipid-soluble medicines are greatly improved. Meanwhile, the albumin nano-preparation keeps the solubility of albumin and a tumor targeting enriching property very well.

The invention relates to a method for building a model for collectively evaluating bioavailability and toxicity of cadmium accumulation in food for a human body, and the method comprises the following steps of (1) food sample digestion and determination liquid acquiring: a, grinding a food sample after the food sample is collected, and sequentially digesting the food sample by sequentially adopting gastric juice and intestinal juice; and b, centrifuging the digested mixed liquid, collecting supernate to be sterilized through high pressure; (2) independently culturing Caco-2 cells and 293T cells; (3) combined culture of Caco-2 cells and 293T cells: moving an insertion groove with the Caco-2 cells into a hexagonal-porous plate with the 293T cells to be continuously cultured for 24h; (4) evaluation of bioavailability and toxicity of cadmium: placing the food sample determination liquid on a Caco-2 cell layer of a combined culture model, simultaneously adding iso-osmotic incubation liquid on a 293T cell layer, and continuing the culture for 24h; in the chronic toxicity test, maximally collectively culturing the sample for 10d; and (5) detecting indexes. The method has characteristics of simpleness in operation, easiness in controlling test conditions, small pollution, economical efficiency, accurate result and the like, and also has the advantages for collectively evaluating the bioavailability and toxicity. The method is suitable for evaluating the safety of the cadmium accumulation in grains, vegetables and animal food.

The present invention provides an intestinal tract targeting and pH-sensitive complex coacervation microcapsule transmission system and a preparation method and an application thereof. Carboxymethyl chitosan and arabic gum are polycations and polyanions to constitute a complex coacervationsystem. By adjusting pH value, the carboxymethyl chitosan and the arabic gum are subjected to complex coacervation reaction, and the complex coacervation phase is collected by centrifugation, crosslinked by genipin, and freeze-dried to obtain the intestinal tract targeting and pH-sensitive complex coacervation microcapsule transmission system. The intestinal tract targeting and pH-sensitive complex coacervation microcapsule transmission system can be used either for embedding water-soluble functional components, but also for embedding fat-soluble functional components, can protect core materials against damage caused by strongly acidic gastric environment, safely delivery the core materials to the intestinal tracts to conduct targeted releases, and expand the practical application field of the complex coacervation microencapsulation technology. The intestinal tract targeting and pH-sensitive complex coacervation microcapsule transmission system does not dissociate in a simulated gastric fluid and swells in a simulated intestinal fluid, and has a strong stability, and the process is simple, safe, efficient, and easy for mass production.

The invention discloses a method for microencapsulating cholesterol-degrading lactic acid bacteria, which comprises the steps of the activation of the cholesterol-degrading lactic acid bacteria, the preparation of immobilized cholesterol-degrading lactic acid bacteria, the preparation of microcapsules by a W/O/W multiphase emulsion method, and freeze-drying. The cholesterol-degrading lactic acid bacteria microcapsules prepared by adopting the multiphase emulsion method (W/O/W) have the characteristics of stability, non-toxicity and the like due to the fact that wall materials thereof all belong to natural polymer materials; the release rate of the microcapsules in intestinal juice within 2h is over 87.4 percent, and the viable count can reach 7.03*109cfu/mL; the viable count can still reach 6.81*106cfu/mL after the microcapsules are placed for 3h at the temperature of 50 DEG C, and can still reach 6*108cfu/mL after the microcapsules are stored for 30d; in vitro cholesterol degradation tests, the degradation rate of cholesterol is over 36.07 percent; and the microcapsules have better acid resistance, enteric property, high temperature resistance and cholesterol degradation, and the yield is about 86.62 percent. Capsule materials and carrier materials have low cost, so the cost is reduced.

The invention belongs to the technical field of functional healthcare food, and discloses a xanthophylls nano dispersion liquid with a control release property. The preparation method of the xanthophylls nano dispersion liquid with the control release property comprises the following steps: dissolving casein-glucan copolymer into water, then rapidly injecting a water phase in an ethyl alcohol phase (in which xanthophylls is dissolved) in stirring by adopting an injection method, removing ethyl alcohol in a system by adopting a rotary evaporation method, carrying out ultra-high-pressure homogenization treatment so as to obtain the xanthophylls nano dispersion liquid, and carrying out freeze-drying to obtain powder with good dispersion. The nano dispersion liquid prepared by the invention has high xanthophylls encapsulation efficiency higher than 90%, has the average particle size of 110-150nm, and the xanthophylls is at the amorphous state. According to the invention, the bioavailability of the xanthophylls is improved, and the xanthophylls nano dispersion liquid as a xanthophylls supplement can be widely applied to industries such as of food industry and health care product industry. The xanthophylls nano dispersion liquid with the control release property and the preparation method thereof have the characteristics that directional grafted copolymer of casein and glucan acts as a wall material, so that the aims of controlling the release of xanthophylls in gastrointestinal tracts, uniformly dispersing in intestinal juice and improving the bioavailability are achieved.

The invention discloses a levofloxacin hydrochloride tablet and a preparation method of the levofloxacin hydrochloride tablet. The preparation is prepared by blending and tabletting medicine-containing particles, citric acidenteric particles and a lubricant, wherein the citric acidenteric particles is prepared by dissolving the citric acid and the polyvinyl acetatephthalic acid ester in ethyl alcohol. According to the invention, the citric acid is wrapped in an enteric material and is not dissolved in the stomach, the citric acid is dissolved and released in the intestines, so that the alkalinity of the intestinal juice is reduced, the levofloxacin hydrochloride is enabled not to be separated out, and therefore, the bioavailability of the medicine is improved.

The present invention relates to a kind of slow-releasing famciclovir capsule for antiviral treatment, and features that the slow-releasing famciclovir capsule is prepared through coating famciclovir medicine with supplementary material to form the pellet core, coating the pellet core with inner release controlling layer of water insoluble polymer, re-coating with outer release controlling layer of enteric polymer to form release controlling famciclovir pellet, and encapsulating famciclovir pellet to form the slow-releasing famciclovir capsule. In artificial gastric juice and artificial intestinal juice, the slow-releasing famciclovir capsule has its medicine releasing degree of 10-30 %, 30-70 % and over 70 % separately in 1.5 hr, 3 hr and 8 hr. The pellet is measured to have medicine content of 56.8-65.2 %.

The invention discloses disodium sulfodehydroabietate (DSDA) and a composition, a preparation method and application thereof in medicaments for preventing hyperacid peptic ulcer and gastrointestinal inflammation. A patent application disclosed by CN00818150.0 is of the opinion that monosodium sulfodehydroabietate is superior to disodium salt, but does not further disclose test conditions and data conclusion; moreover, the pharmacological action and clinical application of the disodium salt deserve further research. The invention compares the in-vitro acid making effects of monosodium salt and the disodium salt, the dissolution of the monosodium salt and the disodium salt in artificial gastric juice and intestinal juice as well as the clinical efficacies in treating gastric ulcer, acute gastritis and acute attack of chronic gastritis. Results show that DSDA has the advantages that DSDA has stronger acid-making capability during treating the gastric ulcer, acute gastritis and acute attack of chronic gastritis and faster dissolution speed in stomach and intestine; and medicaments prepared from the DSDA have better curative effect and quick response.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus paracasei with the effects of reducing blood sugar, protecting the oral cavity and resisting depression and application of the lactobacillus paracasei. The lactobacillus paracasei nbk-LC16 provided by the invention has relatively strong acid resistance and cholate resistance, is good in tolerance in artificial gastric juice and artificial intestinal juice, and can effectively reduce blood sugar and inhibit streptococcus mutans. The influence of the lactobacillus paracasei nbk-LC16 on hyperglycemia mice is studied, and after the lactobacillus paracasei nbk-LC16 is perfused, compared with model group mice, the weight of the hyperglycemia mice is remarkably increased in 8W, the liver index and the spleen index are remarkably reduced, FBG and PBG are remarkably reduced, the HbA1c and insulin levels are remarkably reduced, and the hepatoglycogen content is increased. Test results show that the lactobacillus paracasei nbk-LC16 can regulate blood glucose by regulating insulin level and HbA1c and promoting conversion of blood glucose into hepatic glycogen. Researches on the inhibitioneffect of the streptococcus mutans strain on streptococcus mutans show that the streptococcus mutans strain can be effectively inhibited through in-vitro tests and oral test results, and the oral cavity and tooth health can be protected; meanwhile, the anti-depression effect is achieved.